Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Restart Life Sciences Corp (OP:NMLSF)

0.0829 UNCHANGED
Streaming Delayed Price Updated: 11:33 AM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0829
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0829
Today's Range 0.0829 - 0.0829
52wk Range 0.0123 - 0.0950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
News headline image
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism ↗
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < 
Via Benzinga

Performance

YTD
+225.1%
+225.1%
1 Month
+33.3%
+33.3%
3 Month
+65.8%
+65.8%
6 Month
+75.6%
+75.6%
1 Year
+363.1%
+363.1%

More News

Read More
News headline image
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗
Via Benzinga
News headline image
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder ↗
Via Benzinga
News headline image
Nova Mentis Is Looking To Treat Autism With Psilocybin ↗
Via Benzinga
News headline image
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval ↗
Via Benzinga
News headline image
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗
Via Benzinga
News headline image
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial ↗
Via Benzinga
News headline image
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial ↗
Via Benzinga
News headline image
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin ↗
Via Benzinga
News headline image
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn ↗
Via Benzinga
News headline image
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Via Newsfile
News headline image
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details ↗
Via Benzinga
News headline image
Nova Mentis Completes Production of Psilocybin Microdose Capsules
Via Newsfile
News headline image
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases ↗
Via Benzinga
News headline image
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies ↗
Via Benzinga
News headline image
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened ↗
Via Benzinga
News headline image
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study ↗
Via Benzinga
News headline image
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism ↗
Via Benzinga
News headline image
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market ↗
Via Benzinga
News headline image
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis ↗
Via Benzinga
News headline image
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗
Via Benzinga
News headline image
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗
Via Benzinga
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
Via Benzinga
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Via Benzinga

Frequently Asked Questions

Is Restart Life Sciences Corp publicly traded?
Yes, Restart Life Sciences Corp is publicly traded.
What exchange does Restart Life Sciences Corp trade on?
Restart Life Sciences Corp trades on the OTC Traded
What is the ticker symbol for Restart Life Sciences Corp?
The ticker symbol for Restart Life Sciences Corp is NMLSF on the OTC Traded
What is the current price of Restart Life Sciences Corp?
The current price of Restart Life Sciences Corp is 0.0829
When was Restart Life Sciences Corp last traded?
The last trade of Restart Life Sciences Corp was at 12/23/25 11:33 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.